Brooklyn ImmunoTherapeutics to Present at the Access to Giving Virtual Investor Conference on July 15, 2021
July 12 2021 - 8:15AM
Brooklyn ImmunoTherapeutics LLC (NYSE American: BTX) (“Brooklyn” or
“the Company”), a biopharmaceutical company focused on exploring
the role that cytokine and gene editing/cell therapy can have in
treating patients with cancer, blood disorders, and monogenic
diseases, today announced that Chief Executive Officer Howard J.
Federoff, M.D., Ph.D., will present a corporate overview at the
Access to Giving Virtual Investor Conference being held July 13 –
15, 2021.
Dr. Federoff will deliver his corporate
presentation on July 15 at 9:00am ET.
To receive additional information, request an
invitation or to schedule a one-on-one meeting, please email
angie.goertz@issuerdirect.com.
Investors can register here.
About Brooklyn
ImmunoTherapeuticsBrooklyn is focused on exploring the
role that cytokine-based therapy can have in treating patients with
cancer, both as a single agent and in combination with other
anti-cancer therapies. The company is also exploring opportunities
to advance therapies using leading edge gene editing/cell therapy
technology through its option agreement with Factor
Bioscience/Novellus.
Brooklyn’s most advanced program is studying the
safety and efficacy of IRX-2 in patients with head and neck cancer.
In a Phase 2A clinical trial in head and neck cancer, IRX-2
demonstrated an overall survival benefit. Additional studies are
either underway or planned in other solid tumor cancer
indications.
For more information about Brooklyn and its
clinical programs, please visit www.BrooklynITx.com.
Investor Relations Contact:CORE
IR516-222-2560investors@brooklynitx.com
Media Contact:Jules AbrahamCORE
IR917-885-7378julesa@coreir.com
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Apr 2023 to Apr 2024